Early metabolic response using FDG PET/CT and molecular phenotypes of breast cancer treated with neoadjuvant chemotherapy

Table 5 SUV and changes in SUV based on molecular phenotypes

	No. of Pts	Pre-SUV *	Post-SUV *	ΔSUV% *	HPR (%)
ER
Positive	38	6.4 ± 3.3	3.7 ± 2.1	30 ± 57	3 (7.9)
Negative	40	8.6 ± 4.9	4.1 ± 3.1	48 ± 37	11 (27.5)
		P = 0.047	P = 0.936	P = 0.038	P = 0.037^†
PR
Positive	30	6.5 ± 3.3	3.5 ± 2.4	36 ± 63	3 (10.0)
Negative	48	8.2 ± 4.8	4.2 ± 2.8	42 ± 37	11 (22.9)
		P = 0.187	P = 0.347	P = 0.837	P = 0.226^†
HER2
Positive	17	6.8 ± 3.2	3.2 ± 2.6	51 ± 36	5 (29.4%)
Negative	61	7.7 ± 4.6	4.1 ± 2.7	36 ± 51	9 (14.8%)
		P = 0.818	P = 0.247	P = 0.189	P = 0.164^†
Triple negativity
TNBC	26	9.8 ± 5.3	5.0 ± 3.0	42 ± 35	6 (23.1)
Non-TNBC	52	6.4 ± 3.2	3.4 ± 2.3	38 ± 54	8 (15.4)
		P = 0.008	P = 0.076	P = 0.799	P = 0.404^†
Molecular phenotype
Luminal A/B	40	6.3 ± 3.3	3.6 ± 2.2	33 ± 57	3 (7.5)
HER2	12	6.6 ± 3.2	2.8 ± 2.6	56 ± 39	5 (41.7)
TNBC	26	9.8 ± 5.3	5.0 ± 3.0	42 ± 35	6 (23.1)
		P = 0.016^‡	P = 0.055^‡	P = 0.150^‡	P = 0.018^†
Ki-67
Low expression^§	30	6.2 ± 4.1	3.6 ± 2.6	27 ± 65	4 (13.3)
High expression	41	8.5 ± 4.4	4.0 ± 2.8	49 ± 33	10 (24.4)
		P = 0.018	P = 0.541	P = 0.052	P = 0.367^†

HPR, histopathologic responder; ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2; TNBC, triple negative breast cancer.
* Data are presented as the mean ± standard deviation.
^† P-values are based on Chi square or Fisher's exact test.
^‡ P-values are based on Kruskal-Wallis test, otherwise P-values are based on Mann-Whitney U test, presuming to be non-parametric statistics.
^§ Low expression of Ki-67 was defined as ≤ 5%, and 7 patients were not available for Ki-67 results.

ISSN: 1471-2407